Skip to main content
Premium Trial:

Request an Annual Quote

Affy's eBioscience Divests Western Blot Product Line

NEW YORK (GenomeWeb News) – Affymetrix's eBioscience business has sold its TrueBlot IP/Western blot product line to Rockland Immunochemicals for an undisclosed price.

The TrueBlot reagents are used in cancer, cell signaling, infectious disease, and other life sciences research to generate data in immunoprecipitation and Western blot experiments. Western blotting is performed to determine expression and quantitate target proteins in biological samples.

"As eBioscience continues to focus its efforts on our evolving flow cytometry, immunoassay and immunohistochemistry applications in immunology, oncology and other therapeutic areas, we are pleased that the TrueBlot product line is a strong strategic fit for the Rockland portfolio," Don Tartre, GM of eBioscience, said in a statement.

Affy acquired eBioscience for $315 million earlier this year in an effort to diversify its product offerings.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.